Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 10;39(3):496–512. doi: 10.1161/ATVBAHA.118.312315

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors.

Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 7. — Ponatinib combined with rapamycin enhances AKT (protein kinase B) suppression and ERK1/2 (extracellular signal-regulated kinase) activity. A, Phosphorylation changes of 45 kinases in human umbilical vein endothelial cell (HUVEC)-TIE2-L914F (L914F) relative to HUVEC-TIE2-wild type (WT). B, Immunoblot analysis of HUVEC nontransfected (NT), HUVEC-TIE2-WT, and HUVEC-TIE2-L914F (L914F) with indicated antibodies. C, Immunoblot analysis of HUVEC-TIE2-L914F with listed antibodies. Cells were treated with DMSO (Control), 100 nmol/L ponatinib, 10 nmol/L rapamycin, or combination for 48 h. Immunoblot bands were quantified, data expressed as mean±SD, 1-way ANOVA for multiple comparisons (n=3–4 independent experiments). D, Immunoblot analysis of HUVEC-TIE2-L914F treated with shRNA for c-ABL/ARG or with scrambled sequence (sh Scrambled). E, Western blotting analysis of HUVEC-TIE2-L914F with indicated antibodies. Cells were treated with DMSO (Control), 100 nmol/L ponatinib or 10 µmol/L Wortmannin for 1 h.